Patents by Inventor Wilma Wasco

Wilma Wasco has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • REDUCTION OF BETA-AMYLOID LEVELS BY TREATMENT WITH THE SMALL MOLECULE DIFFERENTIATION-INDUCING FACTOR
    Publication number: 20100311726
    Abstract: The present invention relates to novel uses for a family of small molecules, Differentiation-Inducing Factors (DIFs). It has been discovered that DIFs surprisingly can alter the metabolic processing of amyloid precursor protein (APP) and in turn reduce the level of secreted A?. The metabolic processing of other ?-secretase substrates normally present in cells (Notch and APLP1) is not affected when treated with DIF. The invention provides methods for reducing A? production in mammalian cells that express APP by administering DIF-I, DIF-2, DIF-3, a functionally equivalent analog and or any combination thereof. The invention also provides methods for treating and/or preventing Alzheimer's disease by preferentially reducing A? production.
    Type: Application
    Filed: July 16, 2008
    Publication date: December 9, 2010
    Inventors: Michael Myre, Wilma Wasco, Rudolph E. Tanzi
  • Chromosome 1 gene and gene products related to alzheimer's disease
    Publication number: 20030180880
    Abstract: The present invention discloses nucleic acid molecules encoding AD4 gene products, expression vectors and host cells suitable for expressing such gene products. Also disclosed are methods for treating, preventing, and diagnosing Alzheimer's Disease.
    Type: Application
    Filed: June 24, 2002
    Publication date: September 25, 2003
    Applicant: University of Washington
    Inventors: Rudolph E. Tanzi, Gerard D. Schellenberg, Wilma Wasco, Ephrat Levy-Lahad, Thomas D. Bird, David J. Galas
  • Chromosone 1 gene and gene products related to Alzheimer's Disease
    Patent number: 6468791
    Abstract: The present invention discloses nucleic acid molecules encoding AD4 gene products, expression vectors and host cells suitable for expressing such gene products. Also disclosed are methods for treating, preventing, and diagnosing Alzheimer's Disease.
    Type: Grant
    Filed: August 16, 1999
    Date of Patent: October 22, 2002
    Assignees: The General Hospital Corp., University of Washington
    Inventors: Rudolph E. Tanzi, Gerard D. Schellenberg, Wilma Wasco, Ephrat Levy-Lahad, Thomas D. Bird, David J. Galas
  • Genetic alterations related to familial alzheimer's disease
    Publication number: 20010012626
    Abstract: Isolated nucleic acid molecules are provided encoding human PS1 gene products. Mutant PS1 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of the activity of the PS1 polypeptide and mutants thereof. Also provided are diagnostic methods for detecting Alzheimer's disease and therapeutic methods for treating the same.
    Type: Application
    Filed: February 20, 2001
    Publication date: August 9, 2001
    Applicant: The General Hospital Corporation
    Inventors: Rudolph Tanzi, Wilma Wasco
  • Genetic alterations related to familial alzheimer's disease
    Patent number: 6248555
    Abstract: Isolated nucleic acid molecules are provided encoding human PS1 gene products. Mutant PS1 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of the activity of the PS1 polypeptide and mutants thereof. Also provided are diagnostic methods for detecting Alzheimer's disease and therapeutic methods for treating the same.
    Type: Grant
    Filed: August 30, 1996
    Date of Patent: June 19, 2001
    Assignee: The General Hospital Corporation
    Inventors: Rudolph Tanzi, Wilma Wasco
  • Amyloid precursor-like protein and uses thereof
    Patent number: 5891991
    Abstract: The present invention is directed to isolated amyloid precursor-like proteins (APLPs), nucleotide sequences coding for and regulating expression of these protein, antibodies directed against these proteins, and recombinant vectors and host cells containing the genetic sequences coding for and regulating the expression of these protein sequences. The invention is also directed to isolated genomic. DNA, cDNA anti-sense RNA, and RNA containing the protein sequence. Antibodies can be used to detect an APLP in biological specimens, including, for example, fluid, serum or tissue samples. APLP1 and APLP2 are candidate genes for late onset familial Alzheimer's disease.
    Type: Grant
    Filed: August 6, 1996
    Date of Patent: April 6, 1999
    Assignees: The General Hospital Corporation, The Massachusetts Institute of Technology
    Inventors: Wilma Wasco, Keith Bupp, Margaret Magendantz, Rudolph Tanzi, Frank Solomon
  • Nucleic acid encoding amyloid precursor-like protein and uses thereof
    Patent number: 5851787
    Abstract: The present invention is directed to isolated amyloid precursor-like proteins (APLPs), nucleotide sequences coding for and regulating expression of these protein, antibodies directed against these proteins, and recombinant vectors and host cells containing the genetic sequences coding for and regulating the expression of these protein sequences. The invention is also directed to isolated genomic DNA, cDNA anti-sense RNA, and RNA containing the protein sequence. Antibodies can be used to detect an APLP in biological specimens, including, for example, fluid, serum or tissue samples. APLP1 and APLP2 are candidate genes for late onset familial Alzheimer's disease.
    Type: Grant
    Filed: January 21, 1993
    Date of Patent: December 22, 1998
    Assignees: The General Hospital Corporation, The Massachusetts Institute of Technology
    Inventors: Wilma Wasco, Keith Bupp, Margaret Magendantz, Rudolph Tanzi, Frank Solomon